Insights On Upstream Manufacturing

  1. Patient-Derived Organoids For Cell Therapy Development 8/12/2026

    Patient-derived organoids offer a more accurate way to test cell therapies by preserving the complex tumor environments that determine whether these treatments will actually work.

  2. Moving Beyond Animal Models With iPSC-Based Models 8/12/2026

    Animal models are giving way to iPSC-based systems that better reflect human biology, offering researchers a more accurate and ethical path to drug discovery.

  3. From 2D To Organ-On-A-Chip: Platforms Powering Modern Disease Models 8/12/2026

    Disease modeling has evolved well beyond animal studies, and understanding which platform fits which research question is now a critical skill for modern biology teams.

  4. From DNA To IND In 6 Months: Accelerated Development Backed By Experience 8/10/2026

    A rapid, integrated biologics development strategy can achieve IND readiness in as little as six months by combining parallel workflows, early risk mitigation, advanced technologies, robust analytics, and regulatory planning.

  5. Improving Bioprocessing Outcomes With The CHOZN® Elite Host Cell Line 8/7/2026

    Accelerate cell line development with a host engineered for high expression, streamlined clone selection, flexible gene integration, and scalable industrial performance.

  6. Evaluating Clone Performance And Cell-Specific Productivity 8/6/2026

    See how continuous process monitoring and automated at-line analytics support confident CHO clone ranking, consistent cultivation, and scale-up by connecting pH, viable cell density, and more.

  7. Enhancing Laboratory Efficiency And Accelerating Time To Market 8/6/2026

    Explore how automated screening can accelerate CLD while preserving selection confidence, identifying promising candidates that manual methods may miss, and predicting poor fed-batch performers.

  8. A Comparison To Traditional Clone Screening Platforms 8/6/2026

    See how 46 CHO clones performed across automated, deep-well, and microbioreactor fed-batch cultures, using cell density, viability, and IgG concentration to evaluate clone performance.

  9. Developing Consistent And Reproducible 3D Spheroid Models 8/6/2026

    Improve 3D spheroid consistency by optimizing cell selection, seeding density, and plate geometry. See how practical workflows and comparative data help reduce variability and establish reliability.

  10. iPSC-Derived MSCs Show Comparable Expansion, EV Production, And Immunomodulatory Potential To Primary MSCs 8/6/2026

    iPSC-derived MSCs match primary MSCs in expansion, surface marker expression, EV output, and immunomodulatory function, offering a scalable path to standardized cell therapy manufacturing.